Women and coronary artery disease

References

• Leaf DA. A woman's heart: an update of coronary artery disease risk in women. West J Med 1988: 149(6): 751–7
   PubMedGoogle Scholar
• Vital Statistics of the United States, 1981. Mortality, part A, 1986. Nat Center for Health Statistics, 1986
   Google Scholar
• Hazzard WK. Atherogenesis: why women live longer than men. Geriatrics 1985: 40(1): 42–51, 54
   PubMedGoogle Scholar
• Strong JP, Essen DA. Atherosclerosis. In: Proceedings of the Second International Symposium on Atherosclerosis. New York: Springer-Verlag, 1970: 355–64
   Google Scholar
• Rifkind BM, Segal P. Lipid Research Clinics Program reference values for hyperlipidemia and hypolipidemia. JAMA 1983: 250(14): 1869–72
   PubMed Web of Science ®Google Scholar
• Wahl P, Walden C, Knopp R, et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983: 308(15): 862–7
   PubMed Web of Science ®Google Scholar
• Loop FD, Golding LR, MacMillan JP et al. Coronary artery surgery in women compared with men: analyses of risks and long-term results. J Am Coll Cardiol 1983: 1(2 Pt 1): 383–90
   PubMed Web of Science ®Google Scholar
• Cowley MJ, Mullin SM, Bentivoglio LG, et al. Sex differences in the results of coronary angioplasty in the National Heart, Lung, and Blood Institute PTCA registry experience. (Abstr) Circulation 1983: 68(Suppl III): III–97
   PubMedGoogle Scholar
• Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257(23): 3233–40 [erratum, JAMA 1988: 259(18): 2698]
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Smoking and health, a national status report. Rockville, MD: Dept of Health and Human Services, 1987: DHHS publication No. (HHS/PHS/CDC) 87–8396
   Google Scholar
• Shapiro S, Slone D, Rosenberg L, et al. Oral- contraceptive use in relation to myocardial infarction. Lancet 1979: 1(8119): 743–7
   PubMed Web of Science ®Google Scholar
• Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension: the Framingham Study. Circulation 1980: 61(6): 1179–82
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984: 251(3): 351–64
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo, O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987: 317(20): 1237–45
   PubMed Web of Science ®Google Scholar
• The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988: 148(1): 36–69
   PubMedGoogle Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989: 79(1): 8–15
   PubMed Web of Science ®Google Scholar
• Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986: 112(2): 432–7
   PubMed Web of Science ®Google Scholar
• Gordon T, Kannel WB, Hjortland MC, et al. Menopause and coronary heart disease: the Framingham Study. Ann Intern Med 1978: 89(2): 157–61
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988: 319(20): 1313–7
   PubMed Web of Science ®Google Scholar
• Wilson PW Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. N Engl J Med 1985: 313(17): 1038–43
   PubMed Web of Science ®Google Scholar
• Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987: 75(6): 1102–9
   PubMed Web of Science ®Google Scholar
• Criqui MH, Suarez L, Barrett-Connor E, et al. Postmenopausal estrogen use and mortality: results from a prospective study in a defined, homogeneous community. Am J Epidemiol 1988: 128(3): 606–14
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Wingard DL. Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am J Epidemiol 1983: 118(4): 489–96
   PubMed Web of Science ®Google Scholar
• Van Itallie TB. Health implications of overweight and obesity in the United States. Ann Intern Med 1985: 103(6 Pt 2): 983–8
   PubMed Web of Science ®Google Scholar
• Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983: 67(5): 968–77
   PubMed Web of Science ®Google Scholar
• Lapidus L, Bengtsson C, Larsson B, et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. BMJ (Clin Res) 1984: 289(6454): 1257–61
   PubMed Web of Science ®Google Scholar
• Shimokata H, Muller DC, Andres R. Studies in the distribution of body fat. III. Effects of cigarette smoking. JAMA 1989: 261(8): 1169–73
   PubMed Web of Science ®Google Scholar
• Haynes SG, Feinleib M, Kannel WB. The relationship of psychosocial factors to coronary heart disease in the Framingham Study. III. Eight-year incidence of coronary heart disease. Am J Epidemiol 1980: 111(1): 37–58
   PubMed Web of Science ®Google Scholar
• Colditz GA, Willett WC, Stampfer MJ, et al. A prospective study of age at menarche, parity, age at first birth, and coronary heart disease in women. Am J Epidemiol 1987: 126(5): 861–70
   PubMed Web of Science ®Google Scholar